I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Biostage (BSTG) offering of 20 M common and 100% warrant coverage at $0.40

February 10, 2017

  The offering was discounted from $0.50 and was completed at an overnight -$0.10 discount for gross proceeds of $8 M. BSTG closed at $0.30.  

BioTime (NYSEMKT: BTX) Proposes offering of 6.48 M shares at $2.70

February 9, 2017

  BTX had closed FLAT on Thursday at $3.01 and is trading DOWN -$0.25 or -8.31% to $2.76 on Friday am - SELL ​10% discount ... with possible $18.5 M of proceeds  

RegMed Investors’ (RMi) mid-day analysis, momentum has a short fuse

February 9, 2017

  In either direction I live it hourly; you get to read it    

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.